Gilead Sciences and MacroGenics entered into a licensing and collaboration pact worth up to $1.7 billion to develop a bispecific antibody to treat hematological cancers.
Kineta, Inc. struck a collaboration deal with Merck to pair its anti-VISTA monoclonal antibody with Keytruda (pembrolizumab) as a potential treatment for advanced solid tumors, the companies announced Monday.
Moderna Inc. (MRNA.O) has agreed to provide its new variant-adapted COVID-19 vaccine to the global scheme aiming to deliver shots to the world’s poorest people.
Pittsburgh-based NeuBase is diverting resources from its Huntington’s program and shedding 60% of its workforce in a strategic restructuring, the company announced Friday.
Sage Therapeutics and Biogen’s zuranolone met its primary and key secondary endpoints in the Phase III SKYLARK study of women with postpartum depression (PPD), the companies announced Monday.
ReutersMajor U.S. retailers will begin selling lower-cost hearing aids without a prescription or medical exam under final Biden administration rules that take effect Monday.
Yesterday the Supreme Court turned down Novartis’ bid to block the launch of generic versions of the company’s blockbuster multiple sclerosis drug Gilenya in a dispute with China’s HEC Pharm Co Ltd and other generic drugmakers.
One year after BridgeBio and its partners won accelerated approval for liver cancer drug Truseltiq (infigratinib), the company is pulling a planned Phase III program after its partner announced plans to permanently discontinue distribution of the drug on Wednesday.
Novartis said on Thursday that it would cut up to 400 jobs in Ireland, or about a quarter of its workforce there, as part of a previously announced restructuring program that will cut 8,000 jobs globally.
New Delhi is “seriously investigating” the deaths of 69 children in Gambia in the wake of a report that provisionally linked the fatalities to Indian-made products, the South Asian nation’s foreign minister told his Gambian counterpart on Thursday.
